Dr. Lindsay Bornheimer's research program focuses on understanding and preventing suicide death among adults experiencing serious mental illness, with a specific focus on psychosis and schizophrenia. Her work aims to examine suicide risk and protective factors, advance theories of suicide, develop and test behavioral interventions, and increase the utility and scalability of evidence-informed interventions in mental health care. As an intervention and implementation science researcher by training with expertise in cognitive behavioral therapy, she is particularly focused on the adaptation and implementation of cognitive-behavioral approaches in the treatment of serious mental illness and suicide prevention. Bornheimer is currently the principal investigator of a NIMH R34 to modify and test the feasibility, acceptability and preliminary effectiveness of a cognitive-behavioral suicide prevention-focused intervention tailored to adults diagnosed with schizophrenia spectrum disorders in community mental health (R34MH123609). Additionally, she is the site principal investigator of a NIMH R01 to develop and evaluate the feasibility of a simulated assessment tool of cognitive behavioral therapy sills for mental health service providers (R01MH112625).
Bornheimer was trained in a pre-doctoral fellowship at the McSilver Institute for Poverty Policy and Research at New York University and completed a post-doctoral fellowship at the Brown School of Social Work of Washington University in St. Louis. As a licensed clinical social worker, she has over ten years of experience in psychotherapy with individuals, couples and families in both public and private settings. She completed her clinical training at the New York State Psychiatric Institute and New York Presbyterian Hospital and receives training in cognitive behavioral therapy from the Beck Institute.
Bornheimer is also an assistant professor in the University of Michigan Department of Psychiatry and a faculty member of the Depression Center, Injury Prevention Center, and Treatment Innovation and Dissemination Research group.